Condition (MeSH)
Sarcoma, Clear Cell
ClinicalTrials.gov lists 27 trials for Sarcoma, Clear Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
27 of the 27 trials are tagged with Sarcoma, Clear Cell itself; the rest are tagged with a narrower condition beneath it.
When did Sarcoma, Clear Cell trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Not applicable
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 3 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 49 months across 13 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Sarcoma, Clear Cell trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 1/2 | 5 |
| Phase 2 | 10 |
| Phase 2/3 | 1 |
| Not applicable | 4 |
How many Sarcoma, Clear Cell trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 6 |
| Active, not recruiting | 4 |
| Completed | 9 |
| Terminated | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Sarcoma, Clear Cell trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Salarius Pharmaceuticals, LLC | 2 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 |
| Cornerstone Pharmaceuticals | 1 |
| ECOG-ACRIN Cancer Research Group | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Sarcoma, Clear Cell? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 3 |
| TOPOTECAN | 2 |
| Seclidemstat | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ifosfamid | 3 |
| Doxorubicine | 3 |
| Pazopanib Pill | 2 |
| second generation 4-1BBζ B7H3-EGFRt-DHFR | 1 |
| Cisplatin 1 | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Sarcoma, Clear Cell trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile neutropenia | 21 | 1 |
| Thromboembolic event | 11 | 3 |
| Vomiting | 10 | 3 |
| Wound dehiscence | 10 | 2 |
| Anemia | 9 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Sarcoma, Clear Cell? (13)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children's Oncology Group studies AREN0321 and AREN03B2. | Cancer | 2024 | Yes |
| Melanin-targeted [<sup>18</sup>F]-PFPN PET imaging may shed light for clear cell sarcoma. | European journal of nuclear medicine and molecular imaging | 2023 | Yes |
| Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. | Annals of oncology : official journal of the European Society for Medical Oncology | 2017 | Yes |
| Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report. | BMC cancer | 2015 | Yes |
| Outcomes of patients with revised stage I clear cell sarcoma of kidney treated in National Wilms Tumor Studies 1-5. | International journal of radiation oncology, biology, physics | 2013 | Yes |
Showing 5 of 13 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.